Trial Profile

Stimulant and Risperidone in Children With Severe Physical Aggression

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methylphenidate (Primary) ; Risperidone (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Therapeutic Use
Acronyms TOSCA

Most Recent Events

01 Dec 2017 Results assessing clinical implications of the treatment, published in the Journal of the American Academy of Child and Adolescent Psychiatry
01 Jun 2016 Primary endpoint has been met. (NCBRF-TIQ D-Total Score), as per an article published in the Journal of the American Academy of Child and Adolescent Psychiatry.
01 Jun 2016 52-week results (n= 108) published in the Journal of the American Academy of Child and Adolescent Psychiatry

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com